{"id":104327,"date":"2025-05-21T11:43:02","date_gmt":"2025-05-21T09:43:02","guid":{"rendered":"https:\/\/www.pcb.ub.edu\/gerard-caellas-cbo-of-splicebio-our-technology-places-us-at-the-frontier-of-knowledge-and-makes-our-therapy-unique-in-the-world\/"},"modified":"2025-05-21T14:49:33","modified_gmt":"2025-05-21T12:49:33","slug":"gerard-caellas-cbo-of-splicebio-our-technology-places-us-at-the-frontier-of-knowledge-and-makes-our-therapy-unique-in-the-world","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/en\/gerard-caellas-cbo-of-splicebio-our-technology-places-us-at-the-frontier-of-knowledge-and-makes-our-therapy-unique-in-the-world\/","title":{"rendered":"Gerard Caelles, CBO of SpliceBio: “Our technology places us at the frontier of knowledge and makes our therapy unique in the world”"},"content":{"rendered":"

SpliceBio<\/a> is a biotech company pioneering the use of protein splicing to develop a new generation of genetic therapies. Since its founding in 2020, it has experienced remarkable growth, reflecting the innovative potential of its own technology for the treatment of ophthalmological and central nervous system disorders.<\/p>\n

Through the use of inteins and the protein splicing technique, SpliceBio has developed its first gene therapy, SB-007, aimed at Stargardt’s disease, an inherited retinal disorder caused by mutations in the ABCA4 gene. This is the most common form of juvenile macular degeneration, which causes a progressive loss of central vision and can lead to blindness, currently without any approved treatment. Currently, its main therapy, SB-007, “is in the clinical phase and the aim is to be able to provide patients with the correct copy of the missing gene that causes the disease”, says Gerard Caelles<\/strong>, SpliceBio’s Chief Business Officer (CBO).<\/p>\n

“This is a technology that was developed by our founders at Princeton University and that puts us at the frontier of knowledge, which makes our Stargardt disease programme unique in the world”, explains the CBO.<\/p>\n

In this interview conducted during the last edition of the Coffee Connection networking event, Gerard Caelles<\/strong> talks about the main innovations that are being carried out at SpliceBio, where the company is heading and how being part of the innovative ecosystem of the Barcelona Science Park benefits them.<\/p>\n